Bio Screening Industry News

Munich and Freiburg, Germany, May 7, 2008 / b3c newswire / – CRELUX and ProQinase announced today that they have entered into a joint agreement to supply customers with crystal-grade protein kinases and readily available kinase complex structures.

Under the agreement, CRELUX and ProQinase will establish and continuously expand an off-the-shelf crystal-grade protein kinase portfolio, optimized and quality-controlled for successful crystallization. In addition, the two companies will work closely together to provide new crystal-grade protein or crystal structures, tailored to meet customers’ needs.

Recombinant protein kinases, optimized for crystallization, will be produced and exclusively marketed by ProQinase, while CRELUX will continue to provide customers with crystallization and x-ray crystallography services. CRELUX will support ProQinase by performing crystallization quality control for each crystal grade protein batch. At the same time, ProQinase will grant CRELUX privileged direct access to kinase crystal-grade protein.

“This new joint crystal-grade kinase platform offers tremendous advantages: It enables us to continue to focus on our core expertise – complex structure solution – while leveraging the expertise of ProQinase to significantly strengthen our capacities in protein expression,” commented Dr. Michael Schäffer, CEO of CRELUX.

“The combination of CRELUX’s expertise in protein crystallography and ProQinase’s know-how in kinase cloning and expression makes the two companies the partners of choice for all customers interested in kinase crystallography,” noted Dr. Christoph Schächtele, CEO of ProQinase.

CRELUX has used its state-of-the-art structural biology platform to solve more than 250 crystal and co-crystal structures for pharma and biotech companies. This platform encompasses all steps – from target cloning and expression all the way to high-throughput protein crystallization and in-house x-ray crystallography.

ProQinase, as part of its integrated protein kinase technology platform, offers more than 150 recombinant human protein kinases – all produced in-house – and provides all types of in vitro testing services, with more than 220 protein kinases.

Notes to editors

CRELUX GmbH ( www.crelux.com) provides fast and affordable access to co-crystal structures for biotech and pharma companies worldwide. Three dimensional structures of target-compound complexes are unique sources of information during the rational drug discovery process. Straightforward availability of structural data at an early stage of the drug development process significantly enhances productivity and success rates during hit selection, lead generation, and lead optimization. CRELUX has streamlined the processes of structure generation and solved hundreds of co-crystal structures using an integrated technology platform. In addition to customer designed projects crystallization conditions of numerous relevant therapeutic targets are available within the Off-The-Shelf Program of CRELUX. Off-The-Shelf target structures are delivered at a fixed price and short turn around times, facilitating affordable access to structural information.

ProQinase GmbH ( www.proqinase.com) provides an Integrated Protein Kinase Technology (iProKiTe®) Platform for preclinical drug development of protein kinase inhibitors. More than 150 highly active recombinant kinases are offered for sale and more than 220 kinases are available for in vitro testing services (HTS and selectivity profiling etc.). Cellular and in vivo test systems including orthotopic tumor models allow further testing of lead compounds. A Clinical biomarker analysis service supports the evaluation of clinical trials.

Boston, USA — April 29, 2008 — Today at the Bio-IT World Conference & Expo in Boston, USA, CLC bio announced collaboration with Microsoft Corp. on integrating CLC bio’s extensive bioinformatics solutions with Microsoft’s software platform, for the benefit of companies, corporations, and institutions in the biotech, pharmaceutical, and life science sectors. CLC bio has already added support for Microsoft SQL Server in its database solution, CLC Bioinformatics Database, as well as support for Microsoft’s high-performance computing solutions, Windows Compute Cluster Server 2003 and Windows HPC Server 2008.

Dr. Rudy Potenzone, worldwide pharmaceutical industry technology strategist at Microsoft Corp. and director of the Bio IT Alliance, states,
‘We are delighted to work together with CLC bio, a member of the Bio IT Alliance and one of the world’s leading bioinformatics solution providers. This collaboration will ultimately help life sciences firms transition to the Microsoft platform throughout their research and development departments. CLC bio’s tools, fully integrated with the Microsoft Office System, increase ease of use and expand the number of potential users, while reducing administrative overhead and creating a lean workflow. Furthermore, CLC bio’s internationally renowned experts are available for consulting and customized development.’

Jan Lomholdt, Vice President at CLC bio, continues,
‘With our support for Microsoft’s server solutions, the first step in the process has already been taken. The second step is to further advance our collaboration in areas such as Next Generation Sequencing and high-performance computing, which ultimately can help realize the potential of personalized medicine. As a former member of Microsoft’s World Wide Advisory Council, I have first hand experience of the strength and potential Microsoft brings to the table with a collaboration like this, which of course is interesting for a company like ours.’

Windows HPC Server 2008, the successor to Windows Compute Cluster Server 2003, includes a common set of High Performance Computing productivity tools that reaches across desktop and clusters, including a new Parallel Computing Initiative for multicore development. CLC bio’s high-performance computing solution for servers and clusters, CLC Bioinformatics Cell, supports Microsoft’s Message Passing Interface (MPI) in order to run bioinformatics algorithms such as HMMER, ClustalW, and Smith-Waterman on Windows HPC Server 2008 installations.

All CLC bio’s solutions are cross-platform, running on Windows 2000, Windows XP, Windows Vista, as well as Mac OS X and Linux

About CLC bio
CLC bio is the world’s leading full-service bioinformatics solution provider, solely focusing on the development of bioinformatics: software, hardware, data analysis, and custom-designed bioinformatics algorithms.

CLC bio’s mission is to be among the most innovative bioinformatics companies in the 21st century. This is realized through:

Development of bioinformatics software and hardware based on the latest scientific findings
User-friendly, integrated and intuitive cross-platform software solutions
Continuous focus on customer needs and superior customer service
Frequent product updates including the latest IT technologies and bioinformatics algorithms
A flexible IT architecture, enabling customers to buy or develop individualized solutions at a reasonable price

Boston, USA — April 25, 2008 — On Monday, April 28, CLC bio will officially unveil their new Next Generation Sequencing solution, CLC Genomics Workbench, the first comprehensive analysis package which can analyze and visualize data from all the major Next Generation Sequencing (NGS) platforms, such as SOLiD from Applied Biosystems, 454 GS flx from Roche Applied Science, Solexa from Illumina, and HeliScope from Helicos. The World Premiere is at the Bio-IT World Conference & Expo,April 28 - April 30, at the World Trade Center in Boston, USA.

Vice President of CLC bio, Jan Lomholdt, states, Having experienced massive pre-release interest from people within the Next Generation Sequencing segment, we’re confident that our cross-platform NGS solution which includes an intuitive graphical interface, numerous downstream analyses, and support for all the major NGS platforms, will become a hit. Especially when taking into consideration that we have assembled half a million 454 reads against the full E.coli reference genome, in around 2 minutes on a Dual-core laptop with 1 gigabyte RAM. In other words: This is FAST!”

“There is an explosion of interest in the next generation sequencing field right now, and I’m confident that CLC Genomics Workbench will become a valuable tool for the rapidly growing number of users in academia and industry who are using these new instruments for an amazing range of applications,” said Bio-IT World Editor-in-Chief Kevin Davies, PhD. “We’re also delighted that CLC bio has choosen this year’s Bio-IT World Expo in Boston to announce and introduce this product to the scientific and informatics communities.”

CLC Genomics Workbench includes accelerated assembly of Next Generation Sequencing data through use of High Performance Computing technology, making the assembly process very fast. The genomes to be assembled can be of any size, only limited by the number of gigabytes of RAM available on the computer running the assembly.

CLC Genomics Workbench takes full advantage of “paired end” data, and supports a number of features and work-tasks, such as reference assembly of genomes, De Novo assembly of genomes, SNP detection using advanced statistical models, Digital Gene Expression, metagenomics, clustering and assembly of EST and cDNA sequences, large amounts of genomics and transcriptomics downstream analyses, and workflow support. Some of the mentioned features will be implemented in future releases.

CLC Genomics Workbench has already been chosen as Next Generation Sequencing platform for all Danish universities. CLC bio will release CLC Genomics Workbench to the public in late May. To read more about CLC Genomics Workbench go to: www.clcbio.com/genomics

About CLC bio
CLC bio is the world’s leading full-service bioinformatics solution provider, solely focusing on the development of bioinformatics: software, hardware, data analysis, and custom-designed bioinformatics algorithms.

CLC bio’s mission is to be among the most innovative bioinformatics companies in the 21st century. This is realized through:

Development of bioinformatics software and hardware based on the latest scientific findings
User-friendly, integrated and intuitive cross-platform software solutions
Continuous focus on customer needs and superior customer service
Frequent product updates including the latest IT technologies and bioinformatics algorithms
A flexible IT architecture, enabling customers to buy or develop individualized solutions at a reasonable price

Copenhagen & Aarhus Denmark, March 11, 2007 — CLC bio and Department of Biology, Faculty of Science at University of Copenhagen, have signed a site license agreement for CLC bio’s premier bioinformatics software solution, CLC Combined Workbench, in combination with CLC bio’s Educational Suite. The deal runs for five years and is for several hundred seats, giving every researcher, student and teacher access to the software at all times.

The Head of Department of Biology at University of Copenhagen, Professor Dr. Lene Lange states,
‘We chose CLC bio as our solution provider as CLC Combined Workbench provides cutting edge algorithms and analyses of a high scientific standard, which is fundamental for our research. Also the wide range of tools available in this single application will eliminate a lot of tedious tasks, importing, exporting, and converting data between various applications - and thus help us improve our workflow, freeing up valuable time for research. We’re also looking forward to using CLC Educational Suite as a solid backbone for our bioinformatics courses.’

University of Copenhagen’s Department of Biology is organized in different Research Centers which are involved in international top tier research collaborations. They are funded from sources like the European Union and the Bill & Melinda Gates Foundation, among others. The many projects range from retrieval of ancient DNA from fossils (Center for Ancient Genetics), bioinformatics, gene regulations and SNP (Cancer Research), complex dependent mutations, primates genome evolution (The Genomics Group), whole genome sequencing of hyperthermophilic archaea bacteria (Archaea Biology Group), muscle biology (Copenhagen Muscle Research Center) to studies of how climate changes affects distribution of life on Earth (Center for Macroecology).

CLC Combined Workbench is a comprehensive software solution for advanced DNA, RNA, and protein analyses, containing all features of CLC DNA Workbench, CLC RNA Workbench, and CLC Protein Workbench in one, integrated software package. The program will replace the whole range of outdated and expensive tools, which the research centers have been using previously. CLC Combined Workbench is available for Mac OS X, Windows, and Linux

About CLC bio
CLC bio is the world’s leading full-service bioinformatics solution provider, solely focusing on the development of bioinformatics: software, hardware, data analysis, and custom-designed bioinformatics algorithms.

CLC bio’s mission is to be among the most innovative bioinformatics companies in the 21st century. This is realized through:

Development of bioinformatics software and hardware based on the latest scientific findings
User-friendly, integrated and intuitive cross-platform software solutions
Continuous focus on customer needs and superior customer service
Frequent product updates including the latest IT technologies and bioinformatics algorithms
A flexible IT architecture, enabling customers to buy or develop individualized solutions at a reasonable price

Visakhpatnam, Andhra Pradesh, India – December 20, 2007 — CLC bio today announced the signing of a Memorandum of Understanding at an official ceremony at Andhra University, one of the most prestigious universities in India.

Under the agreement, Andhra University and 25 affiliated post graduate colleges will implement CLC bio’s educational solutions as an integrated part of their curriculum. CLC bio provides their top-line sequence analysis software, CLC Combined Workbench, to the university and colleges as well as training of the teachers and provision of customized education materials like PowerPoint slides, exercises, and more.

At the signing ceremony, Professor L. Venu Gopal Reddy, Vice Chancellor of Andhra University stated,
‘Its our great pleasure to announce this collaboration with CLC bio India. We are very happy to state that from now on Andhra University will be a dedicated user of CLC bio’s bioinformatics solutions in all our life science departments like Biotechnology, Microbiology, Biochemistry, Botany and Human Genetics. We consider CLC bio to be the premier bioinformatics solution provider in the world and this agreement will support education in Andhra University significantly. We are very proud to say that this agreement generates a significant competitive advantage compared to most other universities in India and abroad, in the field of bioinformatics and life sciences.’

Thomas Knudsen, Chief Executive Officer in the CLC bio Group continued,
‘I am honored to be attending the signing ceremony of this important agreement. I am sure that the use of our Educational Solutions - already implemented at a large number of universities in Europe, USA, and India - will bring Andhra University and the affiliated colleges a great step forward in their work to be among the top universities in India and abroad. I am also very happy with the extensive future collaboration which is a part of the agreement, ensuring that CLC bio’s Educational Solutions will always stay at pace with the fast moving educational sector in India.’

The software implementation and training will be carried out by CLC bio India which is headquartered in Hyderabad, Andhra Pradesh.

For more information on CLC bio’s educational solutions, go to:
www.clceducation.com

About CLC bio
CLC bio is the world’s leading full-service bioinformatics solution provider, solely focusing on the development of bioinformatics: software, hardware, data analysis, and custom-designed bioinformatics algorithms. CLC bio is an Apple solution provider and value added reseller.

CLC bio’s mission is to be among the most innovative bioinformatics companies in the 21st century. This is realized through:

Development of bioinformatics software and hardware based on the latest scientific findings
User-friendly, integrated and intuitive cross-platform software solutions
Continuous focus on customer needs and superior customer service
Frequent product updates including the latest IT technologies and bioinformatics algorithms
A flexible IT architecture, enabling customers to buy or develop individualized solutions at a reasonable price

Odense & Aarhus, Denmark — December 18, 2007 — ACE BioSciences, an emerging pharmaceutical company focused on developing novel protein-based vaccines and antibodies to address infectious diseases, and CLC bio, the world’s leading bioinformatics solutions provider, today announced a collaborative bioinformatics agreement.

Dr. Ingelise Saunders, Chief Executive Officer at ACE BioSciences said,
‘At ACE BioSciences we place considerable emphasis on selecting partners based on their scientific know-how - and in that regard we recognize CLC bio as the leading company within bioinformatics, with a global reputation and internationally renowned experts. We see this collaboration as a significant opportunity to augment and expand our bioinformatics platform to increase efficiency, enhance our analyses, and accelerate our research.’

Dr. Jannick D. Bendtsen, project manager and Senior Scientific Officer at CLC bio commented,
‘We are looking forward to this collaboration, which is scientifically interesting and challenging. The implementation of our customized software will streamline and fast-track analysis and further increase statistical confidence in the selection of novel candidates for inclusion in the ACE BioSciences’ development portfolio. Implementation of automated target validation protocols will increase efficiency and the rate of data throughput, improve quality assurance and enhance data security.’

Under the terms of the agreement, CLC bio will upgrade and expand ACE BioSciences’ existing bioinformatics platform to ensure the company is taking advantage of the most up-to-date, relevant, and innovative software, including state-of-the-art protein vaccine target characterization. In addition, CLC bio will provide greater integration and cross-referencing capabilities, securing for ACE BioSciences the ability to apply more extensive statistical analyses to its databases and laboratory information. CLC bio’s customized solution will strengthen ACE BioSciences’ ability to compare, rank, and prioritize potential vaccine targets.

The solution provided to ACE BioSciences consists of a number of CLC workbenches for DNA, RNA, and protein sequence analysis, supplemented with customized bioinformatics modules that are proprietary for ACE BioSciences

Read more about CLC bio’s customized software solutions on:
www.clcbioconsulting.com

About ACE BioSciences

ACE BioSciences is an emerging pharmaceutical company focused on developing novel protein-based vaccines and antibodies to address infectious diseases. It has unique expertise in the extraction and analysis of the cell surface proteins used by pathogens (eg bacteria, viruses and fungi) to interact with and infect human host cells.

The company’s lead product, ACE393, is an injectable vaccine that is on track to become the world’s first commercial vaccine for Travellers’ Diarrhoea caused by Campylobacter infection, having successfully completed Phase I clinical trials in March 2007.

Campylobacter is one of the greatest causes of gastroenteritis in the developed world as well as a significant contributor to travellers’ diarrhoea. The annual global commercial market for a Campylobacter vaccine is estimated to be worth € 350 million.

ACE BioSciences aims to develop a portfolio of products independently and in collaboration with other companies and as part of that strategy the company signed a collaborative development agreement with the US Naval Medical Research Center (NMRC) to progress ACE393 through Phase II clinical trials. In addition to ACE393, the company is working on ACE537, an oral, Phase I, Enterotoxigenic E Coli (ETEC) vaccine which has the potential to be the first to market in the US and EU and which combats the single biggest cause of travelers diarrhoea. It is also working on a vaccine for Streptococcus pneumoniae, the bacterium responsible for Pneumococcal disease.The market for a Streptococcus product would be multibillion and ACE BioSciences aims to partner the project.

About CLC bio

CLC bio is the world’s leading full-service bioinformatics solution provider, solely focusing on the development of bioinformatics: software, hardware, data analysis, and custom-designed bioinformatics algorithms. CLC bio is an Apple solution provider and value added reseller.

CLC bio’s mission is to be among the most innovative bioinformatics companies in the 21st century. This is realized through:

• Development of bioinformatics software and hardware based on the latest scientific findings
• User-friendly, integrated and intuitive cross-platform software solutions
• Continuous focus on customer needs and superior customer service
• Frequent product updates including the latest IT technologies and bioinformatics algorithms
• A flexible IT architecture, enabling customers to buy or develop individualized solutions at a reasonable price

Munich, Germany – December 6th, 2007 – Definiens, the number one Enterprise Image Intelligence™ company, today unveiled the release of Definiens TissueMap 2.0, highlighting the company’s focus on oncology research. The image analysis software application is especially designed for the detailed, automated morphometric quantification of biomarkers of nuclei or cell bodies in epithelial tumors or xenografts. The application features the detection of viable and necrotic tissue in xenografts, as well as regions of IHC (DAB) positively stained nuclei or cells in the viable tissue. This enables pathologists to automate the process of complex or highly apoptotic xenograft analysis in oncology research.

Effective imaging technologies support pharmaceutical development in oncology

The discovery and application of oncology biomarkers have enhanced opportunities for individual disease treatment by identifying new drug targets. They therefore have a significant impact on the entire process of drug development including the emergence and growth of imaging technologies utilized to acquire accurate measurements of disease parameters.
The effective use of imaging technologies, such as Definiens TissueMap 2.0, significantly improves the selection and prioritization of quality candidates early in the drug development pipeline. This results in substantial cost savings and faster time-to-market as poorer drug candidates are removed early in the discovery process.

Assessment of any biomarkers targeting an antigen located in the nucleus or cell body

Definiens TissueMap 2.0 reliably identifies areas and structures of interest in image data allowing researchers to distinguish between viable and necrotic tumor areas and to quantify markers. It offers:

o Full tissue slide analysis

o Fast and reproducible results

o Platform independence and connectivity

o Easy customization

o Precise measurement of morphological parameters

Definiens TissueMap 2.0 encompasses the assessment of any biomarkers targeting an antigen located in the nucleus such as proliferation markers (Ki67, PCNA, BrdU, etc.), apoptosis markers such as Cap3 as well as estrogen or progesterone receptors. Antibodies or markers co-/located in the cell body, such as cytokeratines (CD31, AE1/3, etc.) and other proteins (CD45, CD23 or similar) can also be evaluated.

Comprehensive software for quantification regardless of staining methodology

Definiens TissueMap 2.0 enables the quantification of biomarker expression patterns in image data regardless of staining methodology. The software application effectively analyzes image data in oncology research, including cases involving poor staining technique and data obtained from heterogeneous equipment.

Definiens TissueMap 2.0 enables the automated detection of relevant morphological structure in tissue and tumor sections. It improves research results through increased data accuracy, consistency and reproducibility.

New information concerning Definiens TissueMap 2.0 was presented at the 7th World Drug Discovery & Development Summit 2007 in Cologne, Germany, December 4-5, 2007, which brought together leading pharmaceutical and biotech professionals to discuss key scientific and strategic challenges.

Definiens in Life Sciences

By automating image analysis on an enterprise level, Definiens supports Life Science organizations to analyze and interpret vast numbers of images accurately and consistently. Definiens improves the measurement of cell assays, the examination of tissue samples and the interpretation of non-invasive imaging, enabling high-content screening, digital pathology and translational medicine.

About Definiens

Definiens is the number one Enterprise Image Intelligence company for analyzing and interpreting images on every scale, from microscopic cell structures to satellite images. The Definiens Cognition Network Technology®, developed by Nobel laureate Prof. Gerd Binnig and his team, is an advanced and robust context-based technology designed to fulfill the image analysis requirements of the Life and Earth sciences markets. The technology is modeled on the powerful human cognitive perception processes to extract intelligence from images. Definiens provides organizations with faster image analysis results, allowing deeper insights enabling better business decisions. The company is headquartered in Munich, Germany and has offices throughout the United States. Further information is available at www.definiens.com.

Definiens, Definiens Cellenger, Definiens Cognition Network Technology, Definiens eCognition, Enterprise Image Intelligence and Understanding Images are trademarks or registered trademarks of Definiens.

Aarhus, Denmark — December 14th, 2007 — CLC bio, the world’s leading bioinformatics solution provider, today announced the release of version 2.0 of CLC RNA Workbench. Among a wide variety of new features, this new release brings user-friendly versions of partition function calculation for RNA secondary structure and minimum energy free scanning - functions previously only available through highly advanced scripting, are now available through a graphical interface for everyone working with RNA research.

Peter Johannes Steffensen, PhD in Mathematics and algorithm expert at CLC bio, states,
‘We have developed our own minimum free energy algorithm and graphical interface to scan for local structure content - a world’s first! This feature is ideal for full genome scans of viruses, or for scanning mRNA for the presence of structural signals. For scientists working with RNA biology this is a very smooth and fast feature for computing significant local RNA structures based on minimum free energy calculation.

Dr. Roald Forsberg, Senior Scientific Officer at CLC bio, continues,
‘Today RNA biology is becoming important in all areas of biomedical research. We are now introducing a graphical interface to view different applications of partition function calculations for RNA secondary structure - another world’s first. With a few clicks of the mouse, scientists are now able to determine the probability for RNA structure elements like base pairs and unpaired regions. This is extremely useful for researchers who design molecules for RNA interference, and need to statistically test complex structure hypotheses.

By introducing a smooth and graphical approach to these functions, CLC bio helps accelerate viral biology research and reaffirms CLC RNA Workbench’s position in the market as the only integrated and professional solution which can help RNA researchers to a considerably more efficient workflow, and thereby save precious time in the research phases. Furthermore, researchers will get higher quality results, due to easy and user-friendly access to the cutting edge algorithms included in CLC RNA Workbench.

CLC bio offers a free 30-day trial of CLC RNA Workbench which can be downloaded from:
www.clcbio.com/rna

About CLC bio
CLC bio is the world’s leading full-service bioinformatics solution provider, solely focusing on the development of bioinformatics: software, hardware, data analysis, and custom-designed bioinformatics algorithms. CLC bio is an Apple solution provider and value added reseller.

CLC bio’s mission is to be among the most innovative bioinformatics companies in the 21st century. This is realized through:

Development of bioinformatics software and hardware based on the latest scientific findings
User-friendly, integrated and intuitive cross-platform software solutions
Continuous focus on customer needs and superior customer service
Frequent product updates including the latest IT technologies and bioinformatics algorithms
A flexible IT architecture, enabling customers to buy or develop individualized solutions at a reasonable price

Aarhus, Denmark — November 29th, 2007 — CLC bio, the world’s leading bioinformatics solution provider, today announced the release of CLC Bioinformatics Database. This powerful and versatile database solution enables research organizations, from small university departments and clinical labs to large biotech and pharmaceutical companies, to maximize their potential, through increased productivity. An increase in productivity will help increase the number of drug candidates, by empowering scientists to do more with their research. In turn this gives companies a more efficient use of R&D budgets.

Dr. Darrol Baker, Sales Manager at CLC bio states,
CLC Bioinformatics Database raises the bar for what can be expected from a database solution! Our development team has focused on eliminating classic obstacles such as different operating systems, limited support for database formats, or limited access to a central storage facility. The security and management facilities in CLC bio’s Bioinformatics Database can potentially help organizations stop misuse or loss of data, as well as help protect their intellectual property rights.

For organizations already having an existing relational database in use for sharing DNA, RNA, and protein sequence data, the CLC Bioinformatics Database interface can be customized to store and retrieve data directly from that database. The result is a solution that enables all users of CLC bio’s software to work directly on - and fully integrated with - the organization’s existing database. This ensures the same data sharing, data searching and data security characteristics as if the database had been a stand alone database - except for the fact that the CLC bio data is now fully integrated with all other sequence data in the organization. The design, API-customization, implementation, and data migration can be carried out by the customer or by CLC bio’s consultants.

As with all other of CLC bio’s solutions, CLC Bioinformatics Database is cross-platform, running on Mac OS X, Windows, and Linux. Additionally, this solution will enable users across various workgroups to work on data in a central, shared, and secure relational database. CLC Bioinformatics Database integrates and runs smoothly with several types of databases, including Oracle, PostgreSQL, and MySQL.

For more information on CLC Bioinformatics Database, go to:
www.clcbio.com/database

About CLC bio

CLC bio is the world’s leading full-service bioinformatics solution provider, solely focusing on the development of bioinformatics: software, hardware, data analysis, and custom-designed bioinformatics algorithms. CLC bio is an Apple solution provider and value added reseller.

CLC bio’s mission is to be among the most innovative bioinformatics companies in the 21st century. This is realized through:

• Development of bioinformatics software and hardware based on the latest scientific findings
• User-friendly, integrated and intuitive cross-platform software solutions
• Continuous focus on customer needs and superior customer service
• Frequent product updates including the latest IT technologies and bioinformatics algorithms
• A flexible IT architecture, enabling customers to buy or develop individualized solutions at a reasonable price

Aarhus, Denmark and Cambridge, UK — November 6, 2007 — CLC bio, the premier bioinformatics solution provider, and Abcam, the world-leading research antibody supplier, today announced that CLC bio has met the first important milestone of the two companies’ collaboration: the development of a customized epitope prediction software solution to augment  Abcam’s high through-put monoclonal antibody development programme.

Through automation of labor intensive manual workflows and by applying expert scientific knowledge, CLC bio’s customized bioinformatics solution ensures a significant reduction in the time-to-marketwhilst ensuring that the antibodies are of the highest quality.

Dr Catherine Onley, Head of Product Development & Manufacture at Abcam, states:
‘We searched the market to find the best bioinformatics solution provider for this highly specialized project and I am more than satisfied with CLC bio’s performance. Their skilled IT developers and experienced bioinformatics scientists and project manager have developed an epitope prediction solution that exceeds our expectations. Abcam’s in-house R&D programme will benefit significantly from this. I look forward to the next phase of our collaboration, where we will fully integrate the epitope prediction solution with our LIMS system.’

Dr Jannick D. Bendtsen, project manager and Senior Scientific Officer at CLC bio, said:
‘We are very proud to help Abcam improve their R&D workflows and performance through this software consulting assignment. From a personal perspective, I’m thrilled to work on this Abcam project as it has been scientifically challenging. I look forward to seeing Abcam improve their competitive edge using this new bioinformatics solution.’

Parts of the epitope prediction functionalities will be included in future versions of CLC Protein Workbench and CLC Combined Workbench, which will facilitate epitope prediction in basic research. The unique Abcam-related work will be kept confidential between the two parties.  The customized epitope prediction software follows CLC bio’s concept of providing highly specialized bioinformatics solutions, based on a highly popular and well-proven platform. The Abcam solution is designed as a plug-in that is then fully integrated with the CLC Combined Workbench, CLC bio’s premier desktop-based DNA, RNA, and protein sequence analysis and data management software.

Read more about CLC bio’s customized software solutions on:
www.clcbioconsulting.com

About CLC bio
CLC bio is the world’s leading full-service bioinformatics solution provider, solely focusing on the development of bioinformatics: software, hardware, data analysis, and custom-designed bioinformatics algorithms. CLC bio is an Apple solution provider and value added reseller.

CLC bio’s mission is to be among the most innovative bioinformatics companies in the 21st century. This is realized through:

Development of bioinformatics software and hardware based on the latest scientific findings
User-friendly, integrated and intuitive cross-platform software solutions
Continuous focus on customer needs and superior customer service
Frequent product updates including the latest IT technologies and bioinformatics algorithms
A flexible IT architecture, enabling customers to buy or develop individualized solutions at a reasonable price
About Abcam, Plc
Abcam plc is a producer and distributor of research-grade antibodies headquartered in Cambridge, UK, with a US office located in Cambridge, Massachusetts, and a Japan office in Tokyo. Abcam was admitted to AIM in November 2005 and trades under the ticker symbol ABC.  The Company produces and distributes its own and third party produced antibodies to academic and commercial customers throughout the world with product information provided and ordering available through the Company’s website, www.abcam.com. The antibodies are sold under the Abcam brand name. The Company’s vision is to build the largest online antibody resource in the world while also ensuring that the antibodies are of high quality and commercially viable. Abcam now has an online catalogue of approximately 35,000 products, most of which are antibodies, from over 200 suppliers supported by up-to-date and detailed technical data sheets, which are created by the Company. The Company currently employs 130 staff in its three operating companies.